Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region

Value in Health

Volumn 11, Issue SUPPL. 1, 2008, Pages

  Chen, Yingyao ^a   Schweitzer, Stuart O ^b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Access; China; Pharmaceutical; Pricing; Reimbursement

Indexed keywords

AMLODIPINE BESYLATE; ATORVASTATIN; CELECOXIB; CLOPIDOGREL; ESOMEPRAZOLE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GABAPENTIN; LANSOPRAZOLE; MONTELUKAST; OLANZAPINE; PANTOPRAZOLE; SERTRALINE; SIMVASTATIN; VENLAFAXINE; ZOLPIDEM TARTRATE;

ASIA; CHINA; CONFERENCE PAPER; DECISION MAKING; DRUG COST; DRUG MARKETING; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; PACIFIC ISLANDS; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 41749097450     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00376.x     Document Type: Conference Paper

References (19)

1. Lansang MA, Alejandria M, Banzon E, et al. A rapid situational analysis of health policy and systems research in the Western Pacific region. A technical report submitted to the World Health Organization, Western Pacific Regional Office, 2006.
2. WHO Asia Pacific Strategy for Emerging Diseases. Manila : WHO, 2005.
3. WHO Strategy on Health Care Financing for Countries of the Western Pacific and South-East Asia Regions (2006-2010). Geneva : WHO, 2005.
4. Wang YR. The Chinese pharmaceutical market at the crossroads: pro-competition solutions to improve access, quality and affordability. Appl Health Econ Health Policy 2005 4 : 147 51.
5. Hu S, Chen W, Cheng X, et al. Pharmaceutical cost-containment policy: experiences in Shanghai, China. Health Policy Plan 2001 16 (Suppl. 2 S4 9.
6. Zhang R, Hu S. An analysis of China's drug expense growth. Chin J Hosp Adm 2002 18 : 648 50.
7. Schweitzer SO. Pharmaceutical Economics and Policy. New York : Oxford University Press, 1997.
8. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003 21 : 89 103.
9. Meng QY, Cheng G, Silver L, et al. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals. Health Policy Plan 2005 20 : 185 96.
10. Zhang YG, Dai W. The puzzle of the pharmaceutical price. Finance 2005 12. Available from: http://caijing.hexun.com/text.aspx?lm=2553&id=1464234 [Accessed October 11, 2006].
11. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotroic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994 331 : 650 5.
12. Towse A. The efficient use of pharmaceuticals: does Europe have any lessons for a medicare drug benefit? Health Aff 2003 22 : 42 6.
13. He ZG. Rational thinking on current policy of containing rapid rise of drug expenditure in our country. China Pharmacy 2005 16 : 1364 6.
14. Spence MM, Teleki SS, Cheetham TC, et al. Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev 2005 62 : 544 59.
15. Steinke DT, MacDonald TM, Davey PG. The doctor-patient relationship and prescribing patterns: a view from primary care. Pharmacoeconomics 1999 16 : 599 603.
16. Bryan S, Gill P, Greenfield S, et al. The myth of agency and patient choice in health care? The case of drug treatments to prevent coronary disease. Soc Sci Med 2006 63 : 2698 701.
17. Kaba R, Sooriakumaran P. The evolution of the doctor-patient relationship. Int J Surg 2007 5 : 57 65.
18. Schweitzer SO, Schweitzer ME, Sourty-LeGuellec MJ. Is there a US drug lag? The timing of pharmaceutical approvals in the G-7 countries and Switzerland. Med Care Res Rev 1996 53 : 162 78.
19. Lichtenberg F. Pharmaceutical Innovation, Mortality Reduction, and Economic Growth. National Bureau for Economic Research Working Paper. New York : NBER, 1998.